论文部分内容阅读
目的:研究3种多药耐药蛋白P-gp、LRP、MRP1在初治的弥漫大B细胞淋巴瘤(DLBCL)两种亚型中的表达差异。方法:选择我院经病理证实的DLBCL初治患者,采用免疫组化方法检测组织标本中CD10、Bcl-6、MUM-1的表达,将其分为GCB和non-GCB两种亚型。免疫组化检测P-gp、LRP、MRP1在每个组织标本中的表达,采用卡方检验的方法比较其在GCB和non-GCB两组中的表达差异。结果:共收集DLBCL患者37例,免疫组化检测分为GCB亚型17例,non-GCB亚型20例。P-gp、LRP、MRP1在DLBCL的表达率分别高达62.2%、94.6%、62.2%,在两组亚型中的表达均没有统计学差异(P=1.0,P=0.49,P=1.0)。结论:初治的DLBCL中GCB和non-GCB两种亚型的预后差异与P-gp、LRP、MRP1这3种多药耐药蛋白的表达无关。
OBJECTIVE: To study the difference of expression of three multidrug resistance proteins P-gp, LRP and MRP1 between two subtypes of newly diagnosed diffuse large B cell lymphoma (DLBCL). Methods: The patients with newly diagnosed DLBCL in our hospital were selected and the expression of CD10, Bcl-6 and MUM-1 in the tissue samples was detected by immunohistochemistry, which were divided into two subtypes: GCB and non-GCB. Immunohistochemistry was used to detect the expression of P-gp, LRP and MRP1 in each tissue specimen. The differences in expression between GCB and non-GCB were compared by chi-square test. Results: A total of 37 patients with DLBCL were collected. Immunohistochemistry was divided into 17 cases of GCB subtype and 20 cases of non-GCB subtype. The expression rates of P-gp, LRP and MRP1 in DLBCL were as high as 62.2%, 94.6% and 62.2%, respectively. There was no significant difference in the expression of P-gp, LRP and MRP1 between the two subtypes (P = 1.0, P = 0.49, P = 1.0). CONCLUSION: The prognostic differences between the two subtypes of GCB and non-GCB in naive DLBCL are not related to the expression of three multidrug resistance proteins, P-gp, LRP and MRP1.